FinTechFunding

Imugene: Receives FDA approval for PD1-Vaxx trial

  • Imugene (IMU) has received approval from the U.S. Food and Drug Administration (FDA) to begin a clinical trial for its PD1-Vaxx drug
  • Then the company gained Investigational New Drug (IND) approval to begin enrolment in a phase one trial in patients with non-small cell lung cancer
  • The primary aim of the phase one study is to determine the safety and optimal dosage of the drug, as well as measuring efficacy and immune response
  • PD1-Vaxx is already in phase one clinical trials in Australia
  • Imugene also cashed up and ready to progress PD1-Vaxx and three other immunotherapies through clinical trials in the current quarter
  • Imugene is trading grey for 5.6 cents
Previous article
Vection Technologies: Shares slip on September quarterly report
Next article
PayGroup: Appoints Shane Gild as Non-Executive Director
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

eToro Strengthens Crypto Portfolio with Zengo Acquisition

Deal expands eToro's offerings in the cryptocurrency sector.Highlights: eToro is acquiring crypto wallet Zengo to expand its services.The...
FinTech

Revolut Launches Platform to Streamline Overseas Talent Hiring

Revolut's new service aims to simplify global recruitment for businesses.Highlights: Revolut launches a platform for hiring overseas talent.The...
FinTech

Revolut Strengthens Business Recruitment Platform in New Markets

The fintech giant expands its offerings targeting recruitment needs globally.Highlights: Revolut enhances its platform for business recruitment.The expansion...
FinTech

UniCredit Selects Slate to Strengthen Retail Investment Services

The partnership aims to enhance digital investment options for customers.Highlights: UniCredit partners with Slate for enhanced retail investment...